Akoya Biosciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $413.34 million
- Book Value:
- Revenue TTM:
- $69.80 million
- Operating Margin TTM:
- Gross Profit TTM:
- $34.22 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Akoya Biosciences Inc had its IPO on 2021-04-16 under the ticker symbol AKYA.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Akoya Biosciences Inc has a staff strength of 319 employees.
Shares of Akoya Biosciences Inc opened at $5.78 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $5.71 - $6.08, and closed at $5.98.
This is a +4.91% increase from the previous day's closing price.
A total volume of 67,730 shares were traded at the close of the day’s session.
In the last one week, shares of Akoya Biosciences Inc have slipped by -0.17%.
Akoya Biosciences Inc's Key Ratios
Akoya Biosciences Inc has a market cap of $413.34 million, indicating a price to book ratio of 6.2478 and a price to sales ratio of 6.6669.
In the last 12-months Akoya Biosciences Inc’s revenue was $69.80 million with a gross profit of $34.22 million and an EBITDA of $-58317000. The EBITDA ratio measures Akoya Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Akoya Biosciences Inc’s operating margin was -92.94% while its return on assets stood at -21.81% with a return of equity of -65.36%.
In Q4, Akoya Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 39.9%.
Akoya Biosciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akoya Biosciences Inc’s profitability.
Akoya Biosciences Inc stock is trading at a EV to sales ratio of 6.4924 and a EV to EBITDA ratio of -7.6503. Its price to sales ratio in the trailing 12-months stood at 6.6669.
Akoya Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $176.03 million
- Total Liabilities
- $37.06 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Akoya Biosciences Inc ended 2023 with $176.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $176.03 million while shareholder equity stood at $58.58 million.
Akoya Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $37.06 million in other current liabilities, 2000.00 in common stock, $-166748000.00 in retained earnings and $18.26 million in goodwill. Its cash balance stood at $74.23 million and cash and short-term investments were $81.22 million. The company’s total short-term debt was $3,629,000 while long-term debt stood at $0.
Akoya Biosciences Inc’s total current assets stands at $112.20 million while long-term investments were $0 and short-term investments were $6.99 million. Its net receivables were $9.73 million compared to accounts payable of $10.63 million and inventory worth $14.49 million.
In 2023, Akoya Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $869000.
Comparatively, Akoya Biosciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Akoya Biosciences Inc stock is currently trading at $5.98 per share. It touched a 52-week high of $16.57 and a 52-week low of $16.57. Analysts tracking the stock have a 12-month average target price of $18.63.
Its 50-day moving average was $6.86 and 200-day moving average was $10.5 The short ratio stood at 5.32 indicating a short percent outstanding of 0%.
Around 1284.3% of the company’s stock are held by insiders while 7928.4% are held by institutions.
Frequently Asked Questions About Akoya Biosciences Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.